The trial was designed to evaluate the therapy’s efficacy and safety in treating AML, as well as myelodysplastic syndromes.

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

TC BioPharm (NASDAQ: TCBP) announced the completion of patient dosing in Cohort A of its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for re ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

PLC ("TC BioPharm" or the "Company")  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...

TC BioPharm (NASDAQ: TCBP) has completed full dosing for the first Cohort B patient in its Phase 2B ACHIEVE clinical trial evaluating TCB008 for acut ...

PLC ("TC BioPharm" or the "Company")  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first ...